Skip to Content
Merck
  • Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m.

Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m.

Scientific reports (2017-11-09)
Javad Garousi, Sarah Lindbo, Bogdan Mitran, Jos Buijs, Anzhelika Vorobyeva, Anna Orlova, Vladimir Tolmachev, Sophia Hober
ABSTRACT

ABD-Derived Affinity Proteins (ADAPTs) is a novel class of engineered scaffold proteins derived from an albumin-binding domain of protein G. The use of ADAPT6 derivatives as targeting moiety have provided excellent preclinical radionuclide imaging of human epidermal growth factor 2 (HER2) tumor xenografts. Previous studies have demonstrated that selection of nuclide and chelator for its conjugation has an appreciable effect on imaging properties of scaffold proteins. In this study we performed a comparative evaluation of the anti-HER2 ADAPT having an aspartate-glutamate-alanine-valine-aspartate-alanine-asparagine-serine (DEAVDANS) N-terminal sequence and labeled at C-terminus with

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, ≥97.0% (CHN)